Life With an Experimental Brain Implant: Six Pioneers on Record

Scott Imbrie, who entered a University of Chicago brain-computer interface (BCI) trial in 2020, has guided a robotic arm with an electrode array implanted in his motor cortex and felt a handshake he had not experienced since a 1985 car accident left him paralyzed from the neck down at age 22. "I still get goosebumps when I think about that initial contact," he says.

The recipient cohort is small enough that more people have traveled to space than have received implanted BCIs of this kind. Every device described below remains investigational; none has received Food and Drug Administration clearance for routine clinical use.

How do these implants actually record from the brain?

Most academic BCI trials rely on intracortical microelectrode arrays—small recording pins driven into the cortical tissue—the dominant example being Blackrock Neurotech's Utah Array, which embeds 96 needlelike electrodes in the motor cortex (the brain region that drives voluntary movement). Decoder algorithms convert the recorded firing patterns into commands for external devices: cursors, robotic limbs, or electrical stimulation systems that reanimate the user's own muscles.

Newer devices alter the recording geometry. Neuralink houses its amplifier and battery in a coin-sized skull-mounted unit linked to flexible electrode threads inserted by a robotic arm. Synchron threads a "stentrode" (a stent-mounted recording lead) through the vasculature and positions contacts against the motor cortex from inside blood vessels—a less invasive route the company argues lowers surgical risk.

What does a BCI trial demand of participants?

Enrollment data illustrate the workload. John Downey, an assistant professor of neurological surgery at the University of Chicago and lead investigator on Imbrie's trial, says 10 to 20 candidates inquire for every participant who ultimately enrolls. Ian Burkhart, the first quadriplegic to regain hand movement through a BCI, attributes the dropoff to upfront disclosures of surgical risk, infection, and the possibility that a working implant might one day be removed.

Burkhart eventually had his device explanted after an infection ended a trial he joined in 2014 at Ohio State University and Battelle Memorial Institute. "It was a little bit of a tease where I got to see the capability of the restoration of function," he says. "Now I'm just back to where I was."

Burden falls on those who remain. Austin Beggin, paralyzed in a 2015 swimming accident, travels more than two hours from Lima, Ohio, to Case Western Reserve University in Cleveland for two-week residencies each month, working three to four hours per day on decoder recalibration. "The mental work of just trying to do something like shaking hands or feeding yourself is 100-fold versus you guys that don't even think about it," Beggin says.

What changes once the implant works?

Emotional gains often exceed functional ones. Casey Harrell, who received a Synchron-derived implant at the University of California, Davis, in July 2023, restored spoken conversation within 30 minutes of activation despite amyotrophic lateral sclerosis (ALS, a neurodegenerative disorder that destroys motor neurons controlling voluntary movement). "I was absolutely overwhelmed with the thought of how this would impact my life and allow me to talk to my family and friends and better interact with my daughter," he says.

Other participants describe equally unexpected dividends. Alex Conley, a Neuralink user who broke his neck in 2021, returned to computer-aided design within days of receiving his device, drafting parts for a 3D printer. "This gives me that same little burst of joy," he says.

Nathan Copeland, who holds the longest-running functional implant in the published record—a University of Pittsburgh system joined in 2015 after a 2004 car accident—argues that small wins matter most. "A lot of tasks that people think are mundane or frivolous are probably the tasks that have the most impact on someone that can't do them," he says. "Agency and freedom of expression, I think, are the things that impact a person's life the most."

What is still holding the technology back?

Scar tissue gradually degrades signal quality, and current intracortical implants last roughly a decade before replacement, Downey says. That limit, combined with finite brain real estate, restricts most users to one or two device cycles in a lifetime.

Most participants operate Blackrock-derived rigs only in a laboratory or a wired home setup. Synchron has begun to address portability by pairing its stentrode with a smartphone-sized relay and an Apple Vision Pro headset that overlays control menus for smart-home devices.

Where is commercial development heading?

Synchron's stentrode is the only chronically implanted BCI in this cohort that is delivered through blood vessels rather than open-skull surgery. Neuralink, by contrast, requires a craniotomy (surgical removal of a bone flap) for each recipient. Both companies are training decoders that adapt to slow shifts in neural firing, reducing recalibration to minutes per session.

Whether the field can scale beyond investigational use will depend partly on patient advocacy. Imbrie argues that consumer-oriented pricing pressure could lower medical costs. "I truly believe that making it a consumer-available product will just enhance the product's capabilities for the medical field," he says.

The BCI Pioneers Coalition, founded by Burkhart in 2018, is now formalizing that voice with industry and federal regulators. Its stated aim: keeping attention on the participants whose daily endurance turns every published milestone into a usable device.